Table 5. Logistic regression analysis with enthesis hypoechogenicity, thickening, enthesophyte, cortical irregularity as dependent variables after correction for body mass index.

	Hypoechogenicity		Thickening		Enthesophyte		Bony irregularity
	O.R.(95% CI)	P value	O.R.(95% CI)	P value	O.R.(95% CI)	P value	O.R.(95% CI)	P value
Age	1.05 (0.97–1.13)	.20	1.03 (0.96–1.11)	.35	1.01(0.96–1.06)	.77	0.97 (0.91–1.03)	.28
Sex	1.56 (0.43–5.72)	.50	1.81 (0.50–6.54)	.36	0.80 (0.33–1.91)	.61	2.32 (0.78–6.95)	.13
T2DM duration	1.06 (0.97–1.16)	.20	1.06 (0.97–1.16)	.18	1.02 (0.96–1.09)	.49	0.95 (0.88–1.04)	.28
OADs treated	2.07 (0.24–17.82)	.51	1.09 (0.95–1.22)	.24	0.57 (0.18–1.79)	.33	2.68 (0.51–14.06)	.24
Insulin treated	2.34 (0.60–9.22)	.22	0.96 (0.22–4.19)	.95	0.93 (0.31–2.76)	.90	1.79 (0.53–6.05)	.35
Statin treated	4.35 (0.53–35.73)	.17	4.86 (0.59–39.8)	.14	0.96 (0.36–2.53)	.93	4.21 (0.89–20.00)	.07
Retinopathy	1.98 (0.55–7.13)	.30	3.16 (0.87–11.55)	.08	5.35 (2.04–14.03)	.001	0.76 (0.25–2.27)	.62
Macrovascular disease	1.29 (0.36–4.59)	.69	0.79 (0.22–2.90)	.73	0.50 (0.19–1.29)	.15	1.01 (0.36–2.85)	.99
Reduced eGFR	0.45 (0.13–1.65)	.23	1.02 (0.28–3.67)	.98	3.15 (1.11–8.96)	.03	0.49 (0.17–1.42)	.19
High blood pressure	0.56 (0.16–1.99)	.37	0.93 (0.27–3.22)	.91	0.94 (0.38–2.29)	.89	1.89 (0.61–5.89)	.27
Mean glucose	1.01 (0.99–1.02)	.58	0.99 (0.97–1.01)	.32	1.01 (1.00–1.03)	.03	1.01	.45
Mean A1c	1.27 (0.81–1.98)	.30	0.86 (0.51–1.44)	.57	1.28 (0.92–1.78)	.15	1.01 (0.69–1.49)	.94
Total cholesterol	0.99 (0.98–1.02)	.91	1.01 (0.99–1.02)	.85	0.99 (0.98–1.01)	.25	0.99 (0.97–1.00)	.14
LDL cholesterol	0.99 (0.97–1.01)	.44	0.99 (0.97–1.01)	.32	0.99 (0.98–1.01)	.31	0.97 (0.95–0.99)	.008

Legend: T2DM, type 2 diabetes mellitus; OADs, oral antidiabetic drugs; eGFR, estimated glomerular filtration rate; A1c, glycated hemoglobin; LDL, low-density lipoprotein.